Skip to Content

121 Results Found

  • Article
  • Open Access
9 Citations
10,813 Views
16 Pages

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function

  • Eric Escobar-Cabrera,
  • Paula Lario,
  • Jason Baardsnes,
  • Joseph Schrag and ,
  • Yves Durocher and
  • Surjit Dixit
  • + 1 author+ 0 author

Asymmetric bispecific antibodies are a rapidly expanding therapeutic antibody class, designed to recognize two different target epitopes concurrently to achieve novel functions not available with normal antibodies. Many therapeutic designs require an...

  • Article
  • Open Access
6 Citations
3,568 Views
16 Pages

Impact of Vaccine-Elicited Anti-Spike IgG4 Antibodies on Fc-Effector Functions Against SARS-CoV-2

  • Katrina Dionne,
  • Alexandra Tauzin,
  • Étienne Bélanger,
  • Yann Desfossés and ,
  • Mehdi Benlarbi,
  • Ling Niu,
  • Guillaume Beaudoin-Bussières,
  • Halima Medjahed,
  • Catherine Bourassa and
  • Andrés Finzi
  • + 8 authors+ 3 authors

3 May 2025

mRNA vaccines have demonstrated considerable efficacy and safety against SARS-CoV-2, limiting the pandemic burden worldwide. The emergence of new variants of concern and the decline in neutralizing activity observed several weeks post-vaccination rei...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
5 Citations
3,985 Views
15 Pages

Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions

  • Rebekah Sherburn,
  • William D. Tolbert,
  • Suneetha Gottumukkala,
  • Andrew P. Hederman and ,
  • Guillaume Beaudoin-Bussières,
  • Sherry Stanfield-Oakley,
  • Marina Tuyishime,
  • Guido Ferrari,
  • Andrés Finzi and
  • Marzena Pazgier
  • + 6 authors+ 1 author

31 August 2021

The generation of a potent vaccine for the prevention and/or control of HIV-1 has been unsuccessful to date, despite decades of research. Existing evidence from both infected individuals and clinical trials support a role for non-neutralizing or weak...

(This article belongs to the Section HIV Vaccines)
  • Article
  • Open Access
1 Citations
2,860 Views
17 Pages

Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice

  • Rebekah Sherburn,
  • William D. Tolbert,
  • Suneetha Gottumukkala,
  • Guillaume Beaudoin-Bussières and ,
  • Andrés Finzi and
  • Marzena Pazgier
  • + 1 author+ 0 author

Fc-mediated effector functions of antibodies, including antibody-dependent cytotoxicity (ADCC), have been shown to contribute to vaccine-induced protection from HIV-1 infection, especially those directed against non-neutralizing, CD4 inducible (CD4i)...

(This article belongs to the Special Issue Structural and Functional Biology of Retroviral Entry)
  • Review
  • Open Access
76 Citations
16,174 Views
24 Pages

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies

  • Hilma J. van der Horst,
  • Inger S. Nijhof,
  • Tuna Mutis and
  • Martine E. D. Chamuleau

19 October 2020

Monoclonal antibody (mAb) therapy has rapidly changed the field of cancer therapy. In 1997, the CD20-targeting mAb rituximab was the first mAb to be approved by the U.S. Food and Drug Administration (FDA) for treatment of cancer. Within two decades,...

(This article belongs to the Special Issue B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL))
  • Review
  • Open Access
461 Views
39 Pages

23 October 2026

Broadly neutralizing antibodies (bNAbs) have emerged as a promising therapeutic strategy for HIV-1 prevention and treatment, but their efficacy extends far beyond their direct antiviral capacity. In addition to traditional Fab-mediated neutralization...

(This article belongs to the Special Issue Therapeutic Antibodies in HIV)
  • Review
  • Open Access
39 Citations
10,240 Views
18 Pages

18 September 2015

The mechanism of antibody-mediated protection is a major focus of HIV-1 vaccine development and a significant issue in the control of viremia. Virus neutralization, Fc-mediated effector function, or both, are major mechanisms of antibody-mediated pro...

(This article belongs to the Special Issue Viral Glycoprotein Structure)
  • Review
  • Open Access
20 Citations
6,293 Views
14 Pages

30 August 2019

Antibodies play a crucial role in host defense against viruses, both by preventing infection and by controlling viral replication. Besides their capacity to neutralize viruses, antibodies also exert their antiviral effects by crystallizable fragment...

(This article belongs to the Special Issue Advances in Antibody-based HIV-1 Vaccine Development)
  • Article
  • Open Access
6 Citations
10,946 Views
14 Pages

Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies

  • Jamie Valeich,
  • Dan Boyd,
  • Manu Kanwar,
  • Daniel Stenzel and ,
  • Deblina De Ghosh,
  • Arpa Ebrahimi,
  • James Woo,
  • Jenny Wang and
  • Alexandre Ambrogelly
  • + 4 authors+ 0 author

23 September 2020

A variety of Fc domain engineering approaches for abrogating the effector functions of mAbs exists. To address some of the limitations of the current Fc domain silencing approaches, we are exploring a less commonly considered option which relies on t...

(This article belongs to the Special Issue New, Old, and Shared Antibody Specificities in Autoimmune Diseases)
  • Article
  • Open Access
37 Citations
26,674 Views
34 Pages

Functional, Biophysical, and Structural Characterization of Human IgG1 and IgG4 Fc Variants with Ablated Immune Functionality

  • Susan H. Tam,
  • Stephen G. McCarthy,
  • Anthony A. Armstrong,
  • Sandeep Somani and ,
  • Sheng-Jiun Wu,
  • Xuesong Liu,
  • Alexis Gervais,
  • Robin Ernst,
  • Dorina Saro and
  • Bernard J. Scallon
  • + 9 authors+ 4 authors

1 September 2017

Engineering of fragment crystallizable (Fc) domains of therapeutic immunoglobulin (IgG) antibodies to eliminate their immune effector functions while retaining other Fc characteristics has numerous applications, including blocking antigens on Fc gamm...

(This article belongs to the Special Issue Monoclonal Antibodies)
  • Article
  • Open Access
4,151 Views
13 Pages

RBD-Protein/Peptide Vaccine UB-612 Elicits Mucosal and Fc-Mediated Antibody Responses against SARS-CoV-2 in Cynomolgus Macaques

  • Shixia Wang,
  • Farshad Guirakhoo,
  • Sivakumar Periasamy,
  • Valorie Ryan and ,
  • Jonathan Wiggins,
  • Chandru Subramani,
  • Brett Thibodeaux,
  • Jaya Sahni,
  • Michael Hellerstein and
  • Alexander Rumyantsev
  • + 8 authors+ 3 authors

29 December 2023

Antibodies provide critical protective immunity against COVID-19, and the Fc-mediated effector functions and mucosal antibodies also contribute to the protection. To expand the characterization of humoral immunity stimulated by subunit protein–...

(This article belongs to the Special Issue COVID Vaccines: Design, Development, and Immune Response Studies)
  • Article
  • Open Access
11 Citations
3,802 Views
17 Pages

A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics

  • Haiyan Sun,
  • Ming Yang,
  • Huafang Lai,
  • Biswas Neupane and ,
  • Audrey Y.-H. Teh,
  • Collin Jugler,
  • Julian K.-C. Ma,
  • Herta Steinkellner,
  • Fengwei Bai and
  • Qiang Chen
  • + 5 authors+ 0 author

11 May 2023

Antibody-dependent enhancement of infection (ADE) is clinically relevant to Dengue virus (DENV) infection and poses a major risk to the application of monoclonal antibody (mAb)-based therapeutics against related flaviviruses such as the Zika virus (Z...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Review
  • Open Access
1 Citations
711 Views
25 Pages

Immune Mechanisms Underlying Neonatal Protection Following Maternal RSV Vaccination

  • Aikaterini I. Nikolaou,
  • Vasileios Giapros,
  • Maria Alexandra Kefala,
  • Nikolaos G. Papanikolaou and ,
  • Maria Baltogianni and
  • Fani Ladomenou
  • + 1 author+ 0 author

Respiratory syncytial virus (RSV) remains a major cause of severe lower respiratory tract infection in early infancy, a period characterized by immunological immaturity and limited capacity for effective antiviral responses. Maternal RSV vaccination...

(This article belongs to the Special Issue Maternal–Fetal Immunity and Antibody Transfer: Molecular Mechanisms and Clinical Implications)
  • Feature Paper
  • Review
  • Open Access
232 Citations
39,993 Views
34 Pages

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment

  • Rena Liu,
  • Robert J. Oldham,
  • Emma Teal,
  • Stephen A. Beers and
  • Mark S. Cragg

17 November 2020

The majority of monoclonal antibody (mAb) therapeutics possess the ability to engage innate immune effectors through interactions mediated by their fragment crystallizable (Fc) domain. By delivering Fc-Fc gamma receptor (FcγR) and Fc-C1q interactions...

(This article belongs to the Special Issue Antibody Engineering for Cancer Immunotherapy)
  • Article
  • Open Access
7 Citations
3,679 Views
13 Pages

Vaccine Platform Comparison: Protective Efficacy against Lethal Marburg Virus Challenge in the Hamster Model

  • Kyle L. O’Donnell,
  • Corey W. Henderson,
  • Hanna Anhalt,
  • Joan Fusco and ,
  • Jesse H. Erasmus,
  • Teresa Lambe and
  • Andrea Marzi
  • + 2 authors+ 0 author

Marburg virus (MARV), a filovirus, was first identified in 1967 in Marburg, Germany, and Belgrade, former Yugoslavia. Since then, MARV has caused sporadic outbreaks of human disease with high case fatality rates in parts of Africa, with the largest o...

(This article belongs to the Section Molecular Immunology)
  • Review
  • Open Access
7 Citations
4,916 Views
35 Pages

24 September 2024

Correlates of Protection (CoP) are biomarkers above a defined threshold that can replace clinical outcomes as primary endpoints, predicting vaccine effectiveness to support the approval of new vaccines or follow up studies. In the context of COVID-19...

(This article belongs to the Special Issue Immune Effectiveness of COVID-19 Vaccines)
  • Review
  • Open Access
826 Views
30 Pages

22 August 2026

Human immunodeficiency virus (HIV) is an enveloped virus with a remarkable capacity for genetic diversification, enabling rapid escape from host immune responses and therapeutic interventions. Despite extensive global efforts, the development of an e...

(This article belongs to the Section Molecular Medicine)
  • Review
  • Open Access
4 Citations
4,054 Views
13 Pages

7 September 2025

The non-structural protein 1 (NS1) of dengue virus (DENV) plays a multifaceted role in viral pathogenesis and immune modulation. Although vaccine strategies have traditionally focused on neutralizing antibodies against the envelope (E) protein, recen...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
20 Citations
9,343 Views
19 Pages

The Impact of Immunoglobulin G1 Fc Sialylation on Backbone Amide H/D Exchange

  • Felix Kuhne,
  • Lea Bonnington,
  • Sebastian Malik,
  • Marco Thomann and ,
  • Cecile Avenal,
  • Florian Cymer,
  • Harald Wegele,
  • Dietmar Reusch,
  • Michael Mormann and
  • Patrick Bulau
  • + 5 authors+ 0 author

1 October 2019

The usefulness of higher-order structural information provided by hydrogen/deuterium exchange-mass spectrometry (H/DX-MS) for the structural impact analyses of chemical and post-translational antibody modifications has been demonstrated in various st...

  • Communication
  • Open Access
13 Citations
3,736 Views
12 Pages

SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity

  • Guillaume Beaudoin-Bussières,
  • Ariana Arduini,
  • Catherine Bourassa,
  • Halima Medjahed and ,
  • Gabrielle Gendron-Lepage,
  • Jonathan Richard,
  • Qinghua Pan,
  • Zhen Wang,
  • Chen Liang and
  • Andrés Finzi
  • + 5 authors+ 0 author

7 June 2022

Viruses use many different strategies to evade host immune responses. In the case of SARS-CoV-2, its Spike mutates rapidly to escape from neutralizing antibodies. In addition to this strategy, ORF8, a small accessory protein encoded by SARS-CoV-2, he...

(This article belongs to the Special Issue Viruses 2022 - At the Leading Edge of Virology Research)
  • Review
  • Open Access
34 Citations
7,122 Views
23 Pages

31 May 2021

Identification of therapeutics against emerging and re-emerging viruses remains a continued priority that is only reinforced by the recent SARS-CoV-2 pandemic. Advances in monoclonal antibody (mAb) isolation, characterization, and production make it...

(This article belongs to the Special Issue Antibodies and B Cell Memory in Viral Immunity)
  • Review
  • Open Access
47 Citations
12,314 Views
19 Pages

Neutrophils and Influenza: A Thin Line between Helpful and Harmful

  • Sneha T. George,
  • Jonathan Lai,
  • Julia Ma,
  • Hannah D. Stacey and ,
  • Matthew S. Miller and
  • Caitlin E. Mullarkey
  • + 1 author+ 0 author

Influenza viruses are one of the most prevalent respiratory pathogens known to humans and pose a significant threat to global public health each year. Annual influenza epidemics are responsible for 3–5 million infections worldwide and approximately 5...

(This article belongs to the Special Issue Immune Responses to Influenza Virus Antigens)
  • Article
  • Open Access
16 Citations
4,521 Views
14 Pages

Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection

  • Ming Yang,
  • Haiyan Sun,
  • Huafang Lai,
  • Biswas Neupane and ,
  • Fengwei Bai,
  • Herta Steinkellner and
  • Qiang Chen
  • + 2 authors+ 0 author

29 March 2023

Monoclonal antibodies (mAb) against the envelope (E) protein of Zika virus (ZIKV) have shown great potential as therapeutics against the Zika epidemics. However, their use as a therapy may predispose treated individuals to severe infection by the rel...

(This article belongs to the Special Issue Plant-Produced Vaccines, Therapeutics and Phytochemicals: Recent Developments, Challenges and Perspectives)
  • Article
  • Open Access
241 Views
24 Pages

Engineering a Trispecific EGFR × c-MET × VEGF Antibody with Multiple Mechanisms of Action for Antitumor Activity in Gastrointestinal Cancer Models

  • Hao Jiang,
  • Ying Jin,
  • Yuqiang Xu,
  • Peng Chen and ,
  • Simin Wu,
  • Zhengxia Zha,
  • Meixia Fu,
  • Guangmao Mu,
  • Bin Ma and
  • Mark L. Chiu
  • + 10 authors+ 5 authors

29 October 2026

Background: A leading cause of cancer-related mortality worldwide, gastrointestinal (GI) cancers are often recalcitrant to single agent therapies. Dysregulations of the EGFR, cMET, and VEGF pathways are frequently observed together in these malignanc...

(This article belongs to the Topic Antibody-Mediated Therapy and Other Emerging Therapies in Cancer Treatment)
  • Review
  • Open Access
156 Citations
33,152 Views
18 Pages

The Ligands for Human IgG and Their Effector Functions

  • Steven W. de Taeye,
  • Theo Rispens and
  • Gestur Vidarsson

25 April 2019

Activation of the humoral immune system is initiated when antibodies recognize an antigen and trigger effector functions through the interaction with Fc engaging molecules. The most abundant immunoglobulin isotype in serum is Immunoglobulin G (IgG),...

(This article belongs to the Special Issue Structure and Function of Antibodies)
  • Perspective
  • Open Access
22 Citations
6,413 Views
17 Pages

Despite global vaccination efforts, influenza virus continues to cause yearly epidemics and periodic pandemics throughout most of the world. Many of us consider the generation of broader, potent and long-lasting immunity against influenza viruses as...

(This article belongs to the Special Issue The Future of Influenza Virus Vaccines—Perspectives from the young investigators' point of view)
  • Article
  • Open Access
13 Citations
6,225 Views
10 Pages

Development of a Macrophage-Based ADCC Assay

  • Melissa B. Uccellini,
  • Sadaf Aslam,
  • Sean T. H. Liu,
  • Fahmida Alam and
  • Adolfo García-Sastre

Fc-dependent effector functions are an important determinant of the in vivo potency of therapeutic antibodies. Effector function is determined by the combination of FcRs bound by the antibody and the cell expressing the relevant FcRs, leading to anti...

(This article belongs to the Special Issue Immune Responses to Influenza Virus Antigens)
  • Review
  • Open Access
21 Citations
11,256 Views
18 Pages

31 August 2021

The fragment crystallizable (Fc) domain of antibodies is responsible for their protective function and long-lasting serum half-life via Fc-mediated effector function, transcytosis, and recycling through its interaction with Fc receptors (FcRs) expres...

(This article belongs to the Section Molecular Biology)
  • Review
  • Open Access
107 Citations
26,825 Views
24 Pages

28 September 2023

Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic antibodies by modifying their Fc regions. Recent advances in the Fc en...

(This article belongs to the Special Issue Recent Advances in Therapeutic Antibody)
  • Review
  • Open Access
141 Citations
23,243 Views
26 Pages

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies

  • Patricia Gogesch,
  • Simone Dudek,
  • Ger van Zandbergen,
  • Zoe Waibler and
  • Martina Anzaghe

19 August 2021

Since the approval of the first monoclonal antibody (mAb) in 1986, a huge effort has been made to guarantee safety and efficacy of therapeutic mAbs. As of July 2021, 118 mAbs are approved for the European market for a broad range of clinical indicati...

(This article belongs to the Special Issue Fc Receptors)
  • Review
  • Open Access
43 Citations
8,801 Views
20 Pages

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

  • Rongyuan Gao,
  • Zizhang Sheng,
  • Chithra C. Sreenivasan,
  • Dan Wang and
  • Feng Li

1 March 2020

Influenza causes millions of cases of hospitalizations annually and remains a public health concern on a global scale. Vaccines are developed and have proven to be the most effective countermeasures against influenza infection. Their efficacy has bee...

(This article belongs to the Special Issue Influenza Virus Vaccines)
  • Article
  • Open Access
18 Citations
14,637 Views
15 Pages

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing Variants

  • Robert Pejchal,
  • Anthony B. Cooper,
  • Michael E. Brown,
  • Maximiliano Vásquez and
  • Eric M. Krauland

22 August 2023

Therapeutic antibodies represent the most significant modality in biologics, with around 150 approved drugs on the market. In addition to specific target binding mediated by the variable fragments (Fvs) of the heavy and light chains, antibodies posse...

(This article belongs to the Special Issue Novel Strategies and Technologies for the Development of Tumor-Specific Antibodies)
  • Review
  • Open Access
112 Citations
30,151 Views
41 Pages

IgE Antibodies: From Structure to Function and Clinical Translation

  • Brian J. Sutton,
  • Anna M. Davies,
  • Heather J. Bax and
  • Sophia N. Karagiannis

22 February 2019

Immunoglobulin E (IgE) antibodies are well known for their role in mediating allergic reactions, and their powerful effector functions activated through binding to Fc receptors FcεRI and FcεRII/CD23. Structural studies of IgE-Fc alone...

(This article belongs to the Special Issue Structure and Function of Antibodies)
  • Review
  • Open Access
24 Citations
8,798 Views
17 Pages

Fc-Receptor Targeted Therapies for the Treatment of Myasthenia gravis

  • Christian W. Keller,
  • Marc Pawlitzki,
  • Heinz Wiendl and
  • Jan D. Lünemann

Myasthenia gravis (MG) is an autoimmune disease in which immunoglobulin G (IgG) antibodies (Abs) bind to acetylcholine receptors (AChR) or to functionally related molecules in the postsynaptic membrane at the neuromuscular junction. IgG crystallizabl...

(This article belongs to the Special Issue Fc Receptors)
  • Article
  • Open Access
4 Citations
3,214 Views
11 Pages

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

  • Ahmed M. Khalil,
  • Michael S. Piepenbrink,
  • Ian Markham,
  • Madhubanti Basu and ,
  • Luis Martinez-Sobrido and
  • James J. Kobie
  • + 1 author+ 0 author

13 July 2023

Influenza B virus (IBV) contributes to substantial influenza-mediated morbidity and mortality, particularly among children. Similar to influenza A viruses (IAV), the hemagglutinin (HA) and neuraminidase (NA) of IBV undergo antigenic drift, necessitat...

(This article belongs to the Section Viral Immunology, Vaccines, and Antivirals)
  • Article
  • Open Access
8 Citations
5,348 Views
14 Pages

Structure and Dynamics of a Site-Specific Labeled Fc Fragment with Altered Effector Functions

  • D. Travis Gallagher,
  • Chris McCullough,
  • Robert G. Brinson,
  • Joomi Ahn and ,
  • John P. Marino and
  • Nazzareno Dimasi
  • + 1 author+ 0 author

Antibody-drug conjugates (ADCs) are a class of biotherapeutic drugs designed as targeted therapies for the treatment of cancer. Among the challenges in generating an effective ADC is the choice of an effective conjugation site on the IgG. One common...

(This article belongs to the Special Issue Recombinant Therapeutic Proteins for Drug Delivery)
  • Article
  • Open Access
11 Citations
2,691 Views
15 Pages

Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine

  • Alexandra Tauzin,
  • Guillaume Beaudoin-Bussières,
  • Mehdi Benlarbi,
  • Manon Nayrac and ,
  • Yuxia Bo,
  • Gabrielle Gendron-Lepage,
  • Halima Medjahed,
  • Josée Perreault,
  • Laurie Gokool and
  • Andrés Finzi
  • + 13 authors+ 8 authors

15 September 2023

While an important part of the world’s population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly n...

(This article belongs to the Special Issue SARS-CoV-2 and mRNA Vaccines)
  • Review
  • Open Access
99 Citations
42,000 Views
23 Pages

Antibody Glycosylation and Inflammation

  • Kai-Ting C. Shade and
  • Robert M. Anthony

25 June 2013

IgG antibodies are the basis of some of the most effective therapeutics developed over the last 20 years. These antibodies are highly specific, have long serum-half lives, and can be produced relatively routinely, making them ideal drugs for immunoth...

(This article belongs to the Special Issue Modes of Antibody Action for Cancer Therapy)
  • Article
  • Open Access
19 Citations
5,163 Views
13 Pages

Eicosanoid Content in Fetal Calf Serum Accounts for Reproducibility Challenges in Cell Culture

  • Laura Niederstaetter,
  • Benjamin Neuditschko,
  • Julia Brunmair,
  • Lukas Janker and ,
  • Andrea Bileck,
  • Giorgia Del Favero and
  • Christopher Gerner
  • + 2 authors+ 0 author

15 January 2021

Reproducibility issues regarding in vitro cell culture experiments are related to genetic fluctuations and batch-wise variations of biological materials such as fetal calf serum (FCS). Genome sequencing may control the former, while the latter may re...

(This article belongs to the Special Issue Integrative Multi-Omics in Biomedical Research)
  • Article
  • Open Access
9 Citations
6,277 Views
18 Pages

Fc-Independent Protection from SARS-CoV-2 Infection by Recombinant Human Monoclonal Antibodies

  • Tal Noy-Porat,
  • Avishay Edri,
  • Ron Alcalay,
  • Efi Makdasi and ,
  • David Gur,
  • Moshe Aftalion,
  • Yentl Evgy,
  • Adi Beth-Din,
  • Yinon Levy and
  • Ohad Mazor
  • + 13 authors+ 8 authors

8 November 2021

The use of passively-administered neutralizing antibodies is a promising approach for the prevention and treatment of SARS-CoV-2 infection. Antibody-mediated protection may involve immune system recruitment through Fc-dependent activation of effector...

(This article belongs to the Special Issue Antibodies, B Cell Responses and Immune Responses to SARS-CoV-2 Infections)
  • Article
  • Open Access
4,250 Views
14 Pages

Fc-Silenced CD89 × EGFR Bispecific Antibodies Promote Neutrophil and Macrophage Antitumor Activity

  • Felix Meiser,
  • Julia Harwardt,
  • Christoph Hahn,
  • Marta Lustig and ,
  • Thomas Valerius and
  • Harald Kolmar
  • + 1 author+ 0 author

Background/Objectives: CD89 (FcaRI), the receptor for immunoglobulin A (IgA), is expressed on myeloid cells, including neutrophils, monocytes, and macrophages. It is known to mediate potent effector functions against tumor cells, but the clinical dev...

(This article belongs to the Section Antibody Discovery and Engineering)
  • Article
  • Open Access
2 Citations
8,786 Views
20 Pages

IgG Subclass Switch in Volunteers Repeatedly Immunized with the Full-Length Plasmodium falciparum Merozoite Surface Protein 1 (MSP1)

  • Veronika Rathay,
  • Kristin Fürle,
  • Viktoria Kiehl,
  • Anne Ulmer and ,
  • Michael Lanzer and
  • Richard Thomson-Luque
  • + 1 author+ 0 author

17 February 2024

Vaccines are highly effective tools against infectious diseases and are also considered necessary in the fight against malaria. Vaccine-induced immunity is frequently mediated by antibodies. We have recently conducted a first-in-human clinical trial...

  • Review
  • Open Access
111 Citations
19,963 Views
12 Pages

12 January 2010

Human IgG has only one conserved glycosylation site located in the Cγ2 domain of the Fc region that accounts for the presence of two sugar moieties per IgG. These IgG sugar cores play a critical role in a number of IgG effector functions. In the pres...

(This article belongs to the Special Issue Monoclonal Antibody)
  • Review
  • Open Access
26 Citations
6,865 Views
17 Pages

Sialylated Immunoglobulins for the Treatment of Immuno-Inflammatory Diseases

  • Yuliya V. Markina,
  • Elena V. Gerasimova,
  • Alexander M. Markin,
  • Victor Y. Glanz and ,
  • Wei-Kai Wu,
  • Igor A. Sobenin and
  • Alexander N. Orekhov
  • + 2 authors+ 0 author

Immunoglobulins are the potent effector proteins of the humoral immune response. In the course of evolution, immunoglobulins have formed extremely diverse types of molecular structures with antigen-recognizing, antigen-binding, and effector functions...

(This article belongs to the Special Issue Immunoglobulins in Inflammation)
  • Feature Paper
  • Article
  • Open Access
26 Citations
10,659 Views
15 Pages

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering

  • Sophia Roßkopf,
  • Klara Marie Eichholz,
  • Dorothee Winterberg,
  • Katarina Julia Diemer and ,
  • Sebastian Lutz,
  • Ira Alexandra Münnich,
  • Katja Klausz,
  • Thies Rösner,
  • Thomas Valerius and
  • Christian Kellner
  • + 9 authors+ 4 authors

17 November 2020

Background: Native cluster of differentiation (CD) 19 targeting antibodies are poorly effective in triggering antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), which are crucial effector functions of th...

(This article belongs to the Special Issue The Role of Complement in Cancer Immunotherapy)
  • Feature Paper
  • Review
  • Open Access
92 Citations
18,350 Views
13 Pages

16 January 2021

Tumor-targeting monoclonal antibodies (mAbs) are the most widely used and characterized immunotherapy for hematologic and solid tumors. The significance of this therapy is their direct and indirect effects on tumor cells, facilitated by the antibody&...

(This article belongs to the Special Issue Monoclonal Antibodies: Applications in Diagnosis and Immunotherapy of Cancer)
  • Review
  • Open Access
7 Citations
5,614 Views
21 Pages

26 November 2023

Background: Myasthenia Gravis (MG) is a rare autoimmune disease presenting with auto-antibodies that affect the neuromuscular junction. In addition to symptomatic treatment options, novel therapeutics include monoclonal antibodies (mAbs). IMGT®,...

(This article belongs to the Section Vaccines, Clinical Advancement, and Associated Immunology)
  • Article
  • Open Access
1 Citations
4,203 Views
15 Pages

Novel BCR-Targeting Fusion Proteins for Antigen-Specific Depletion of Alloreactive B Cells in Antibody-Mediated Rejection

  • Jing Zhang,
  • Leiyan Wei,
  • Lei Song,
  • Xiaofang Lu and ,
  • Liang Tan,
  • Xin Li,
  • Li Fu,
  • Qizhi Luo,
  • Xubiao Xie and
  • Yizhou Zou
  • + 5 authors+ 0 author

9 September 2025

Donor-specific anti-HLA antibodies (DSAs) bind to donor vascular endothelial cells and mediate allograft rejection (AMR), but a clinical challenge for which targeted therapeutic options remain limited. We used a multiplexed single-antigen bead (SAB)...

(This article belongs to the Special Issue Mechanisms of Immune Responses and Therapy)
  • Review
  • Open Access
1,124 Views
31 Pages

15 August 2026

Therapeutic antibodies have transformed the management of infectious diseases, autoimmune disorders, and cancer, yet most approved agents continue to rely on a limited range of IgG-based Fc scaffolds. Consequently, the broader therapeutic potential o...

(This article belongs to the Section Biopharmaceuticals)
  • Article
  • Open Access
2 Citations
5,134 Views
13 Pages

Platform-Specific Fc N-Glycan Profiles of an Antisperm Antibody

  • Ellena Nador,
  • Chaoshuang Xia,
  • Philip J. Santangelo,
  • Kevin J. Whaley and ,
  • Catherine E. Costello and
  • Deborah J. Anderson
  • + 1 author+ 0 author

IgG Fc N-glycosylation is necessary for effector functions and is an important component of quality control. The choice of antibody manufacturing platform has the potential to significantly influence the Fc glycans of an antibody and consequently alt...

of 3